Spreadsheet: 42c5b178-f852-4f70-b14d-6e0be706d8a8
Sheet: Detailed HCDs

2014-15 tariff - detailed high cost drugs
 |  | Key:
 |  | Added/Altered in 2014-15
Drug name | Notes | Category | BNF category | NICE
Abacavir |  | AIDS/HIV antiretrovirals | 5.3.1
Atazanavir |  | AIDS/HIV antiretrovirals | 5.3.1
Cobicistat |  | AIDS/HIV antiretrovirals
Darunavir |  | AIDS/HIV antiretrovirals | 5.3.1
Didanosine |  | AIDS/HIV antiretrovirals | 5.3.1
Dolutegravir |  | AIDS/HIV antiretrovirals
Efavirenz |  | AIDS/HIV antiretrovirals | 5.3.1
Elvitegravir |  | AIDS/HIV antiretrovirals
Elvitegravir with Cobicistat, Emtricitabine and Tenofovir |  | AIDS/HIV antiretrovirals
Elvucitabine |  | AIDS/HIV antiretrovirals
Emtricitabine |  | AIDS/HIV antiretrovirals | 5.3.1
Enfuvirtide |  | AIDS/HIV antiretrovirals | 5.3.1
Etravirine |  | AIDS/HIV antiretrovirals | 5.3.1
Fosamprenavir |  | AIDS/HIV antiretrovirals | 5.3.1
Indinavir |  | AIDS/HIV antiretrovirals | 5.3.1
Lamivudine |  | AIDS/HIV antiretrovirals | 5.3.1
Lopinavir with [NAME] |  | AIDS/HIV antiretrovirals | 5.3.1
Maraviroc |  | AIDS/HIV antiretrovirals | 5.3.1
Nelfinavir |  | AIDS/HIV antiretrovirals | 5.3.1
Nevirapine |  | AIDS/HIV antiretrovirals | 5.3.1
Raltegravir |  | AIDS/HIV antiretrovirals | 5.3.1
Rilpivirine |  | AIDS/HIV antiretrovirals | 5.3.1
[NAME] |  | AIDS/HIV antiretrovirals | 5.3.1
Saquinavir |  | AIDS/HIV antiretrovirals | 5.3.1
Stavudine |  | AIDS/HIV antiretrovirals | 5.3.1
Tenofovir |  | AIDS/HIV antiretrovirals | 5.3.1 | TA173 & In Progress
Tenofovir with Emtricitabine |  | AIDS/HIV antiretrovirals | 5.3.1
Tipranavir |  | AIDS/HIV antiretrovirals | 5.3.1
Vicriviroc |  | AIDS/HIV antiretrovirals
[NAME] |  | AIDS/HIV antiretrovirals | 5.3.1
[NAME] with Lamivudine |  | AIDS/HIV antiretrovirals | 5.3.1
[NAME] with [NAME] and Abacavir |  | AIDS/HIV antiretrovirals | 5.3.1
Tenofovir with Emtricitabine and Efavirenz |  | AIDS/HIV antiretrovirals | 5.3.1
Mepolizumab |  | Allergen Immunotherapy
[NAME] |  | Allergen Immunotherapy | 3.4.2 | TA133 - Adults, TA201 - Children
[NAME] |  | Allergen Immunotherapy
[NAME] inhibitor | (also known as C1-inhibitors) | Allergic emergencies | 3.4.3
Conestat alfa |  | Allergic emergencies | 3.4.3
Ecallantide |  | Allergic emergencies
Icatibant |  | Allergic emergencies | 3.4.3
Amikacin liposomal |  | Antibacterial Drugs
[NAME] | (when delivered via nebulisation/inhalation) | Antibacterial Drugs | 5.1.2.3
Colistimethate sodium | (when delivered via nebulisation/inhalation) | Antibacterial Drugs | 5.1.7 | In Progress
[NAME] | (when delivered via nebulisation/inhalation) | Antibacterial Drugs | 5.1.2
Tobramycin | (when delivered via nebulisation/inhalation) | Antibacterial Drugs | 5.1.4 | In Progress
Amphotericin liposomal |  | Antifungals | 5.2.3
Anidulafungin |  | Antifungals | 5.2.4
[NAME] |  | Antifungals | 5.2.4
Isavuconazole |  | Antifungals
Micafungin |  | Antifungals | 5.2.4
Posaconazole |  | Antifungals | 5.2.1
Voriconazole |  | Antifungals | 5.2.1
[NAME] | (For non-chemotherapy indications - chemotherapy is dealt with separately) | Antineoplastic drugs | 8.1.5 | TA118, [NAME], TA178, TA214 & In Progress
Bortezomib | (For non-chemotherapy indications - chemotherapy is dealt with separately) | Antineoplastic drugs | 8.1.5 | TA129 & TA228
[NAME] | (For non-chemotherapy indications - chemotherapy is dealt with separately) | Antineoplastic drugs | 8.1.5 | TA118, TA145, [NAME], TA176 & In Progress
Cidofovir |  | Cytomegalovirus infection | 5.3.2.2
Foscarnet |  | Cytomegalovirus infection | 5.3.2.2
Ganciclovir |  | Cytomegalovirus infection | 5.3.2.2
Valganciclovir |  | Cytomegalovirus infection | 5.3.2.2
Antihaemophilic Factor/von Willebrand Factor Complex |  | Blood-related products
[NAME] |  | Blood-related products | 2.11
Catridecacog |  | Blood-related products
Defibrotide |  | Blood-related products
Factor IX |  | Blood-related products | 2.11
Factor VII |  | Blood-related products
Factor VIIa |  | Blood-related products | 2.11
Factor VIII |  | Blood-related products | 2.11
Factor [NAME] Protein |  | Blood-related products
Factor VIII inhibitor bypassing factor |  | Blood-related products | 2.11
Factor [NAME] |  | Blood-related products | 2.11
Fibrin sealants |  | Blood-related products
Fibrinogen |  | Blood-related products | 2.11
GlycoPEGylated Factor IX |  | Blood-related products
Porcine Factor |  | Blood-related products
Protein C |  | Blood-related products | 2.11
[NAME] |  | Blood-related products | 2.11
Thrombin |  | Blood-related products |  | IPG060
Turoctocog alfa |  | Blood-related products
[NAME] factor, recombinant |  | Blood-related products
Dibotermin alfa |  | Bone morphogenetic protein
Eptotermin alfa |  | Bone morphogenetic protein
[NAME] |  | Corticosteroids and other immunosuppressants | 8.2.2 | TA85 & TA99
[NAME] |  | Corticosteroids and other immunosuppressants
Abatacept |  | Cytokine modulators | 10.1.3 | TA195, CG79 & TA234
Adalimumab |  | Cytokine modulators | 1.5.3/10.1.3 | TA130, TA143, [NAME], TA187, TA195, TA199 & In Progress
Anakinra |  | Cytokine modulators | 10.1.3
Apremilast |  | Cytokine modulators
[NAME] |  | Cytokine modulators | 10.1.3 | TA 186
Etanercept |  | Cytokine modulators | 10.1.3 | TA35, [NAME], TA130, TA143, TA195, TA199
Golimumab |  | Cytokine modulators | 10.1.3 | TA220, TA224, TA225 & TA233
[NAME] |  | Cytokine modulators | 1.5.3/10.1.3 | TA35, TA130, TA134, TA140, TA143, [NAME], TA187, TA195, TA199
[NAME] | (For non-chemotherapy indications - chemotherapy is dealt with separately) | Cytokine modulators | 10.1.3 | TA65, TA110, TA137, TA174, TA193, TA195, TA226 & In Progress
[NAME] |  | Cytokine modulators
Teduglutide |  | Cytokine modulators
Tocilizumab |  | Cytokine modulators | 10.1.3 | TA198 & In progress
[NAME] |  | Cytokine modulators
Vercirnon |  | Cytokine modulators
Parathyroid hormone |  | Drugs affecting bone metabolism | 6.6.1
Teriparatide |  | Drugs affecting bone metabolism | 6.6.1 | TA161
[NAME] | (For non-chemotherapy indications - chemotherapy is dealt with separately) | Drugs affecting the immune response | 8.2.3
Belatacept |  | Drugs affecting the immune response | 8.2.2 | In Progress
Belimumab |  | Drugs affecting the immune response | 10.1.3 | In Progress
Plerixafor |  | Drugs affecting the immune response | 9.1.7
Ustekinumab |  | Drugs affecting the immune response | 13.5.3 | [NAME]
[NAME] |  | Drugs affecting the immune response
[NAME] globulin |  | Drugs used in hypoplastic, haemolytic, and renal anaemias | 9.1.3
[NAME] |  | Drugs used in hypoplastic, haemolytic, and renal anaemias | 8.2.2
Deferasirox | (For chronic iron overload) | Drugs used in hypoplastic, haemolytic, and renal anaemias - Iron overload | 9.1.3 | In Progress
Deferiprone | (For chronic iron overload) | Drugs used in hypoplastic, haemolytic, and renal anaemias - Iron overload | 9.1.3 | In Progress
Desferrioxamine | (For chronic iron overload) | Drugs used in hypoplastic, haemolytic, and renal anaemias - Iron overload | 9.1.3 | In Progress
Agalsidase alfa |  | Drugs used in Metabolic disorders | 9.8.1
Agalsidase beta |  | Drugs used in Metabolic disorders | 9.8.1
[NAME] alfa |  | Drugs used in Metabolic disorders | 9.8.1
[NAME] |  | Drugs used in Metabolic disorders
[NAME] |  | Drugs used in Metabolic disorders | 9.8.1
Carglumic acid |  | Drugs used in Metabolic disorders | 9.8.1
Carnitine |  | Drugs used in Metabolic disorders | 9.8.1
[NAME] bitartrate |  | Drugs used in Metabolic disorders
Eliglustat |  | Drugs used in Metabolic disorders
Elosulfase alfa |  | Drugs used in Metabolic disorders
Galsulfase |  | Drugs used in Metabolic disorders | 9.8.1
Human Arginate |  | Drugs used in Metabolic disorders | 9.8.2
Idursulfase |  | Drugs used in Metabolic disorders | 9.8.1
Imiglucerase |  | Drugs used in Metabolic disorders | 9.8.1
Laronidase |  | Drugs used in Metabolic disorders | 9.8.1
Mercaptamine |  | Drugs used in Metabolic disorders | 9.8.1
Migalastat |  | Drugs used in Metabolic disorders | 9.8.1
Miglustat |  | Drugs used in Metabolic disorders | 9.8.1
Nitisinone |  | Drugs used in Metabolic disorders | 9.8.1
Sapropterin |  | Drugs used in Metabolic disorders | 9.4.1
Sebelipase alfa |  | Drugs used in Metabolic disorders
Sodium phenylbutyrate |  | Drugs used in Metabolic disorders | 9.8.1
Taliglucerase alfa |  | Drugs used in Metabolic disorders
Tetrahydrobiopterin |  | Drugs used in Metabolic disorders | 9.4.1
Velaglucerase alfa |  | Drugs used in Metabolic disorders | 9.8.1
Filgrastim | (For non-chemotherapy indications - chemotherapy is dealt with separately) | Drugs used in neutropenia | 9.1.6
Lenograstim | (For non-chemotherapy indications - chemotherapy is dealt with separately) | Drugs used in neutropenia | 9.1.6
[NAME] | (For non-chemotherapy indications - chemotherapy is dealt with separately) | Drugs used in neutropenia
Pegfilgrastim | (For non-chemotherapy indications - chemotherapy is dealt with separately) | Drugs used in neutropenia | 9.1.6
Collagenase | (only when used in outpatients) | Enzymes | 10.1.3
Alteplase | Dealt with as an adjustment for Actute Stroke Care BPT only | Fibrinolytic drugs | 2.10.2 | TA52 & TA122
Pegloticase |  | Gout and cytotoxic-induced hyperuricaemia
Rasburicase |  | Gout and cytotoxic-induced hyperuricaemia | 10.1.4
Lixivaptan |  | Growth Hormone & growth hormone Receptor Antagonist
Mecasermin |  | Growth Hormone & growth hormone Receptor Antagonist | 6.7.4
[NAME] |  | Growth Hormone & growth hormone Receptor Antagonist
Pegvisomant |  | Growth Hormone & growth hormone Receptor Antagonist | 6.5.1
Somatropin |  | Growth Hormone & growth hormone Receptor Antagonist | 6.5.1 | TA64 , TA188
Tesamorelin |  | Growth Hormone & growth hormone Receptor Antagonist
Tolvaptan |  | Growth Hormone & growth hormone Receptor Antagonist | 6.5.2
Serelaxin |  | Hypertension and heart failure
Sodium oxybate |  | Hypnotics and anxiolytics | 4.1.1
Aldesleukin |  | Immunomodulating drugs | 8.2.4
[NAME] |  | Immunomodulating drugs | 8.2.4
Cladribine | (For non-chemotherapy indications - chemotherapy is dealt with separately) | Immunomodulating drugs | 8.1.3 | In Progress
[NAME] |  | Immunomodulating drugs | 8.1
Dimethyl fumarate |  | Immunomodulating drugs
Fingolimod |  | Immunomodulating drugs | 8.2.4 | In Progress
Glatiramer |  | Immunomodulating drugs | 8.2.4 | TA32
Interferon alfa |  | Immunomodulating drugs | 8.2.4 | TA75
Interferon Beta |  | Immunomodulating drugs | 8.2.4 | TA32
[NAME] |  | Immunomodulating drugs
Lenalidomide | (For non-chemotherapy indications - chemotherapy is dealt with separately) | Immunomodulating drugs | 8.2.4 | [NAME]
[NAME] |  | Immunomodulating drugs | 8.2.4 | TA127
Nintedanib |  | Immunomodulating drugs
Peginterferon Beta-1a |  | Immunomodulating drugs
[NAME] |  | Immunomodulating drugs
Rilonacept |  | Immunomodulating drugs
Teriflunomide |  | Immunomodulating drugs
Thalidomide | (For non-chemotherapy indications - chemotherapy is dealt with separately) | Immunomodulating drugs | 8.2.4 | TA228
Aragam |  | Intravenous/subcutaneous human normal immunoglobulins | 14.5.1
Flebogamma |  | Intravenous/subcutaneous human normal immunoglobulins | 14.5.1
Flebogammadif |  | Intravenous/subcutaneous human normal immunoglobulins | 14.5.1
Gammagard |  | Intravenous/subcutaneous human normal immunoglobulins | 14.5.1
Gammanorm |  | Intravenous/subcutaneous human normal immunoglobulins | 14.5.1
[NAME] |  | Intravenous/subcutaneous human normal immunoglobulins | 14.5.1
[NAME] |  | Intravenous/subcutaneous human normal immunoglobulins | 14.5.1
Hizentra |  | Intravenous/subcutaneous human normal immunoglobulins | 14.5.1
Intratect |  | Intravenous/subcutaneous human normal immunoglobulins | 14.5.1
Kiovig |  | Intravenous/subcutaneous human normal immunoglobulins | 14.5.1
[NAME] |  | Intravenous/subcutaneous human normal immunoglobulins | 14.5.1
Octagam |  | Intravenous/subcutaneous human normal immunoglobulins | 14.5.1
Privigen |  | Intravenous/subcutaneous human normal immunoglobulins | 14.5.1
Sandoglobulin |  | Intravenous/subcutaneous human normal immunoglobulins | 14.5.1
Subcuvia |  | Intravenous/subcutaneous human normal immunoglobulins | 14.5.1
Subgam |  | Intravenous/subcutaneous human normal immunoglobulins | 14.5.1
Vigam |  | Intravenous/subcutaneous human normal immunoglobulins | 14.5.1
Vivaglobin |  | Intravenous/subcutaneous human normal immunoglobulins | 14.5.1
Lomitapide |  | Lipid-regulating drugs
Dexamethasone intravitreal implant |  | [NAME] | 11.4.1 | TA229
Fluocinolone acetonide | (only when used as an intravitreal implant) | [NAME]
Dornase alfa |  | Mucolytics | 3.7
Ivacaftor |  | Mucolytics | 3.7
[NAME] | (when delivered via nebulisation/inhalation) | Mucolytics | 3.7
Azacitidine | (For non-chemotherapy indications - chemotherapy is dealt with separately) | Myelodysplastic Syndrome | 8.1.3 | TA218
Decitabine | (For non-chemotherapy indications - chemotherapy is dealt with separately) | Myelodysplastic Syndrome | 8.1.3 | In Progress
Rigosertib | (For non-chemotherapy indications - chemotherapy is dealt with separately) | Myelodysplastic Syndrome
Co-careldopa internal tube intestinal gel | (Only when used as intestinal gel with internal tube) | Neurodegenerative Conditions | 4.9.1
Tafamidis |  | Neurodegenerative Conditions | 4.9.3
Amifampridine phosphate |  | [NAME] | 10.2.1
[NAME] | (For non-cystic fibrosis indications) | [NAME]
Fampridine |  | [NAME] | 10.2.1
Ziconotide |  | Non-opioid analgesics | 4.7.1
Parenteral Nutrition | (after 14 days or when the patient is receiving parenteral nutrition prior to admission) | Parenteral Nutrition | 9.3 | IPG232 & CG32
Eculizumab |  | Paroxysmal nocturnal haemoglobinuria | 9.1.3
[NAME] |  | Platelet Disorder Drugs
Eltrombopag |  | Platelet Disorder Drugs | 9.1.4 | TA205
Romiplostim |  | Platelet Disorder Drugs | 9.1.4 | TA221
Digoxin immune fab |  | Poisoning
Fomepizole |  | Poisoning
Axitinib | (For non-chemotherapy indications - chemotherapy is dealt with separately) | Protein kinase inhibitors | 8.1.5
Crizotinib | (For non-chemotherapy indications - chemotherapy is dealt with separately) | Protein kinase inhibitors | 8.1.5
Dasatinib | (For non-chemotherapy indications - chemotherapy is dealt with separately) | Protein kinase inhibitors | 8.1.5 | In Progress
Erlotinib | (For non-chemotherapy indications - chemotherapy is dealt with separately) | Protein kinase inhibitors | 8.1.5 | TA162, TA227 & In Progress
Everolimus | (For non-chemotherapy indications - chemotherapy is dealt with separately) | Protein kinase inhibitors | 8.1.5 | TA219
Fostamatinib disodium | (For non-chemotherapy indications - chemotherapy is dealt with separately) | Protein kinase inhibitors
Gefitinib | (For non-chemotherapy indications - chemotherapy is dealt with separately) | Protein kinase inhibitors | 8.1.5 | TA175, [NAME]
Imatinib | (For non-chemotherapy indications - chemotherapy is dealt with separately) | Protein kinase inhibitors | 8.1.5 | TA70, TA86, TA196, TA209 & In Progress
Lapatinib | (For non-chemotherapy indications - chemotherapy is dealt with separately) | Protein kinase inhibitors | 8.1.5 | In Progress
Masitinib | (For non-chemotherapy indications - chemotherapy is dealt with separately) | Protein kinase inhibitors
Nilotinib | (For non-chemotherapy indications - chemotherapy is dealt with separately) | Protein kinase inhibitors | 8.1.5 | In Progress
Pacritinib | (For non-chemotherapy indications - chemotherapy is dealt with separately) | Protein kinase inhibitors
Pazopanib | (For non-chemotherapy indications - chemotherapy is dealt with separately) | Protein kinase inhibitors | 8.1.5
Ruxolitinib | (For non-chemotherapy indications - chemotherapy is dealt with separately) | Protein kinase inhibitors | 8.1.5
Sorafenib | (For non-chemotherapy indications - chemotherapy is dealt with separately) | Protein kinase inhibitors | 8.1.5 | TA178, TA189 & In Progress
Sunitinib | (For non-chemotherapy indications - chemotherapy is dealt with separately) | Protein kinase inhibitors | 8.1.5 | [NAME], TA178, TA179
Temsirolimus | (For non-chemotherapy indications - chemotherapy is dealt with separately) | Protein kinase inhibitors | 8.1.5 | TA178 & TA207
Vandetanib | (For non-chemotherapy indications - chemotherapy is dealt with separately) | Protein kinase inhibitors | 8.1.5
[NAME] | (For non-chemotherapy indications - chemotherapy is dealt with separately) | Protein kinase inhibitors | 8.1.5
Pirfenidone |  | Pulmonary Fibrosis | 3.11 | In Progress
Beractant |  | [NAME] surfactants | 3.5.2
Poractant alfa |  | [NAME] surfactants | 3.5.2
Ketorolac with Phenylephrine |  | Retinal disorders/intraocular lens replacement surgery
Ocriplasmin |  | Retinal disorders/intraocular lens replacement surgery | 11.8.2
Afamelanotide |  | Skin Conditions
Alitretinoin |  | Skin Conditions | 13.5.1 | TA177
Fibroblast growth factor 1 gene therapy |  | [NAME]
Lanreotide |  | [NAME] | 8.3.4.3
Octreotide |  | [NAME] | 8.3.4.3
Pasireotide |  | [NAME] | 8.3.4.3
Aflibercept |  | Subfoveal choroidal neovascularisation | 11.8.2
[NAME] |  | Subfoveal choroidal neovascularisation | 11.8.2 | TA155 & In Progress
[NAME] |  | Subfoveal choroidal neovascularisation | 11.8.2 | TA155 & TA237
[NAME] |  | Subfoveal choroidal neovascularisation | 11.8.2
Botulinum toxin |  | Torsion Dystonias and other involuntary movements | 4.9.3 | IPG80
Riluzole |  | Torsion Dystonias and other involuntary movements | 4.9.3 | TA20
Ambrisentan |  | Vasodilator antihypertensive drugs/Pulmanory Arterial Hypertension | 2.5.1
Bosentan |  | Vasodilator antihypertensive drugs/Pulmanory Arterial Hypertension | 2.5.1
Epoprostenol |  | Vasodilator antihypertensive drugs/Pulmanory Arterial Hypertension | 2.8.1
Iloprost |  | Vasodilator antihypertensive drugs/Pulmanory Arterial Hypertension | 2.5.1
Macitentan |  | Vasodilator antihypertensive drugs/Pulmanory Arterial Hypertension
Nitric Oxide |  | Vasodilator antihypertensive drugs/Pulmanory Arterial Hypertension
Riociguat |  | Vasodilator antihypertensive drugs/Pulmanory Arterial Hypertension
Selexipag |  | Vasodilator antihypertensive drugs/Pulmanory Arterial Hypertension
Sildenafil | (only when used for Pulmanory Arterial Hypertension) | Vasodilator antihypertensive drugs/Pulmanory Arterial Hypertension | 2.5.1
Tadalafil | (only when used for Pulmanory Arterial Hypertension) | Vasodilator antihypertensive drugs/Pulmanory Arterial Hypertension | 7.4.5
Treprostinil sodium |  | Vasodilator antihypertensive drugs/Pulmanory Arterial Hypertension
Adefovir |  | Viral Hepatitis (B&C) & Respiratory Syncytial Virus | 5.3.3 | TA96
Alisporivir |  | Viral Hepatitis (B&C) & Respiratory Syncytial Virus
Asunaprevir with [NAME] |  | Viral Hepatitis (B&C) & Respiratory Syncytial Virus
Boceprevir |  | Viral Hepatitis (B&C) & Respiratory Syncytial Virus | 5.3.3 | In Progress
Entecavir |  | Viral Hepatitis (B&C) & Respiratory Syncytial Virus | 5.3.3 | TA153 & In Progress
Faldaprevir |  | Viral Hepatitis (B&C) & Respiratory Syncytial Virus
Filibuvir |  | Viral Hepatitis (B&C) & Respiratory Syncytial Virus
[NAME] |  | Viral Hepatitis (B&C) & Respiratory Syncytial Virus
Nitazoxanide |  | Viral Hepatitis (B&C) & Respiratory Syncytial Virus
[NAME] |  | Viral Hepatitis (B&C) & Respiratory Syncytial Virus | 5.3.5
[NAME] interferon alfa |  | Viral Hepatitis (B&C) & Respiratory Syncytial Virus | 8.2.4 | TA75, TA96, TA106, TA200 & In Progress
Ribavirin |  | Viral Hepatitis (B&C) & Respiratory Syncytial Virus | 5.3.5 | TA75, TA106, TA200 & In Progress
Simeprevir |  | Viral Hepatitis (B&C) & Respiratory Syncytial Virus
Sofosbuvir |  | Viral Hepatitis (B&C) & Respiratory Syncytial Virus
[NAME] with Ledipasvir |  | Viral Hepatitis (B&C) & Respiratory Syncytial Virus
Taribavirin |  | Viral Hepatitis (B&C) & Respiratory Syncytial Virus
Telaprevir |  | Viral Hepatitis (B&C) & Respiratory Syncytial Virus | 5.3.3
Telbivudine |  | Viral Hepatitis (B&C) & Respiratory Syncytial Virus | 5.3.3 | TA154
Drug name | Notes | PbR category | BNF category | NICE
Abiraterone |  | Hormone antagonists | 8.3.4
Enzalutamide |  | Hormone antagonists | 8.3.4.2